Literature DB >> 26819049

Frequent CTLA4-CD28 gene fusion in diverse types of T-cell lymphoma.

Hae Yong Yoo1, Pora Kim2, Won Seog Kim3, Seung Ho Lee4, Sangok Kim5, So Young Kang6, Hye Yoon Jang7, Jong-Eun Lee7, Jaesang Kim8, Seok Jin Kim3, Young Hyeh Ko9, Sanghyuk Lee10.   

Abstract

CTLA4 and CD28 are co-regulatory receptors with opposite roles in T-cell signaling. By RNA sequencing, we identified a fusion between the two genes from partial gene duplication in a case of angioimmunoblastic T-cell lymphoma. The fusion gene, which codes for the extracellular domain of CTLA4 and the cytoplasmic region of CD28, is likely capable of transforming inhibitory signals into stimulatory signals for T-cell activation. Ectopic expression of the fusion transcript in Jurkat and H9 cells resulted in enhanced proliferation and AKT and ERK phosphorylation, indicating activation of downstream oncogenic pathways. To estimate the frequency of this gene fusion in mature T-cell lymphomas, we examined 115 T-cell lymphoma samples of diverse subtypes using reverse transcriptase polymerase chain reaction analysis and Sanger sequencing. We identified the fusion in 26 of 45 cases of angioimmunoblastic T-cell lymphomas (58%), nine of 39 peripheral T-cell lymphomas, not otherwise specified (23%), and nine of 31 extranodal NK/T cell lymphomas (29%). We further investigated the mutation status of 70 lymphoma-associated genes using ultra-deep targeted resequencing for 74 mature T-cell lymphoma samples. The mutational landscape we obtained suggests that T-cell lymphoma results from diverse combinations of multiple gene mutations. The CTLA4-CD28 gene fusion is likely a major contributor to the pathogenesis of T-cell lymphomas and represents a potential target for anti-CTLA4 cancer immunotherapy. Copyright© Ferrata Storti Foundation.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26819049      PMCID: PMC5013939          DOI: 10.3324/haematol.2015.139253

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


  27 in total

1.  Fusion of NUP214 to ABL1 on amplified episomes in T-cell acute lymphoblastic leukemia.

Authors:  C Graux; J Cools; C Melotte; H Quentmeier; A Ferrando; R Levine; J R Vermeesch; M Stul; B Dutta; N Boeckx; A Bosly; P Heimann; A Uyttebroeck; N Mentens; R Somers; R A F MacLeod; H G Drexler; A T Look; D G Gilliland; L Michaux; P Vandenberghe; I Wlodarska; Peter Marynen; Anne Hagemeijer
Journal:  Nat Genet       Date:  2004-09-12       Impact factor: 38.330

2.  BCL2 mutations are associated with increased risk of transformation and shortened survival in follicular lymphoma.

Authors:  Cristina Correia; Paula A Schneider; Haiming Dai; Ahmet Dogan; Matthew J Maurer; Amy K Church; Anne J Novak; Andrew L Feldman; Xiaosheng Wu; Husheng Ding; X Wei Meng; James R Cerhan; Susan L Slager; William R Macon; Thomas M Habermann; Judith E Karp; Steven D Gore; Neil E Kay; Diane F Jelinek; Thomas E Witzig; Grzegorz S Nowakowski; Scott H Kaufmann
Journal:  Blood       Date:  2014-12-01       Impact factor: 22.113

3.  Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence.

Authors:  Giulio Genovese; Anna K Kähler; Robert E Handsaker; Johan Lindberg; Samuel A Rose; Samuel F Bakhoum; Kimberly Chambert; Eran Mick; Benjamin M Neale; Menachem Fromer; Shaun M Purcell; Oscar Svantesson; Mikael Landén; Martin Höglund; Sören Lehmann; Stacey B Gabriel; Jennifer L Moran; Eric S Lander; Patrick F Sullivan; Pamela Sklar; Henrik Grönberg; Christina M Hultman; Steven A McCarroll
Journal:  N Engl J Med       Date:  2014-11-26       Impact factor: 91.245

4.  Recurrent TET2 mutations in peripheral T-cell lymphomas correlate with TFH-like features and adverse clinical parameters.

Authors:  François Lemonnier; Lucile Couronné; Marie Parrens; Jean-Philippe Jaïs; Marion Travert; Laurence Lamant; Olivier Tournillac; Therese Rousset; Bettina Fabiani; Rob A Cairns; Tak Mak; Christian Bastard; Olivier A Bernard; Laurence de Leval; Philippe Gaulard
Journal:  Blood       Date:  2012-07-03       Impact factor: 22.113

5.  Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics.

Authors:  Roland Schmitz; Ryan M Young; Michele Ceribelli; Sameer Jhavar; Wenming Xiao; Meili Zhang; George Wright; Arthur L Shaffer; Daniel J Hodson; Eric Buras; Xuelu Liu; John Powell; Yandan Yang; Weihong Xu; Hong Zhao; Holger Kohlhammer; Andreas Rosenwald; Philip Kluin; Hans Konrad Müller-Hermelink; German Ott; Randy D Gascoyne; Joseph M Connors; Lisa M Rimsza; Elias Campo; Elaine S Jaffe; Jan Delabie; Erlend B Smeland; Martin D Ogwang; Steven J Reynolds; Richard I Fisher; Rita M Braziel; Raymond R Tubbs; James R Cook; Dennis D Weisenburger; Wing C Chan; Stefania Pittaluga; Wyndham Wilson; Thomas A Waldmann; Martin Rowe; Sam M Mbulaiteye; Alan B Rickinson; Louis M Staudt
Journal:  Nature       Date:  2012-08-12       Impact factor: 49.962

6.  Enhancement of antitumor immunity by CTLA-4 blockade.

Authors:  D R Leach; M F Krummel; J P Allison
Journal:  Science       Date:  1996-03-22       Impact factor: 47.728

7.  Recurrent somatic mutations of PTPN1 in primary mediastinal B cell lymphoma and Hodgkin lymphoma.

Authors:  Jay Gunawardana; Fong Chun Chan; Adèle Telenius; Bruce Woolcock; Robert Kridel; King L Tan; Susana Ben-Neriah; Anja Mottok; Raymond S Lim; Merrill Boyle; Sanja Rogic; Lisa M Rimsza; Chrystelle Guiter; Karen Leroy; Philippe Gaulard; Corinne Haioun; Marco A Marra; Kerry J Savage; Joseph M Connors; Sohrab P Shah; Randy D Gascoyne; Christian Steidl
Journal:  Nat Genet       Date:  2014-02-16       Impact factor: 38.330

8.  Somatic RHOA mutation in angioimmunoblastic T cell lymphoma.

Authors:  Mamiko Sakata-Yanagimoto; Terukazu Enami; Kenichi Yoshida; Yuichi Shiraishi; Ryohei Ishii; Yasuyuki Miyake; Hideharu Muto; Naoko Tsuyama; Aiko Sato-Otsubo; Yusuke Okuno; Seiji Sakata; Yuhei Kamada; Rie Nakamoto-Matsubara; Nguyen Bich Tran; Koji Izutsu; Yusuke Sato; Yasunori Ohta; Junichi Furuta; Seiichi Shimizu; Takuya Komeno; Yuji Sato; Takayoshi Ito; Masayuki Noguchi; Emiko Noguchi; Masashi Sanada; Kenichi Chiba; Hiroko Tanaka; Kazumi Suzukawa; Toru Nanmoku; Yuichi Hasegawa; Osamu Nureki; Satoru Miyano; Naoya Nakamura; Kengo Takeuchi; Seishi Ogawa; Shigeru Chiba
Journal:  Nat Genet       Date:  2014-01-12       Impact factor: 41.307

9.  Personalized treatment of Sézary syndrome by targeting a novel CTLA4:CD28 fusion.

Authors:  Aleksandar Sekulic; Winnie S Liang; Waibhav Tembe; Tyler Izatt; Semyon Kruglyak; Jeffrey A Kiefer; Lori Cuyugan; Victoria Zismann; Christophe Legendre; Mark R Pittelkow; John J Gohmann; Fernando R De Castro; Jeffrey Trent; John Carpten; David W Craig; Timothy K McDaniel
Journal:  Mol Genet Genomic Med       Date:  2014-11-27       Impact factor: 2.183

Review 10.  CD28 and CTLA-4 coreceptor expression and signal transduction.

Authors:  Christopher E Rudd; Alison Taylor; Helga Schneider
Journal:  Immunol Rev       Date:  2009-05       Impact factor: 12.988

View more
  28 in total

1.  Functional analysis of acquired CD28 mutations identified in cutaneous T cell lymphoma.

Authors:  Grzegorz B Gmyrek; Jeanette Pingel; Jaehyuk Choi; Jonathan M Green
Journal:  Cell Immunol       Date:  2017-07-10       Impact factor: 4.868

Review 2.  Update on the classification of T-cell lymphomas, Hodgkin lymphomas, and histiocytic/dendritic cell neoplasms.

Authors:  Akira Satou; N Nora Bennani; Andrew L Feldman
Journal:  Expert Rev Hematol       Date:  2019-07-31       Impact factor: 2.929

3.  Genetic alterations affecting GTPases and T-cell receptor signaling in peripheral T-cell lymphomas.

Authors:  Rebecca L Boddicker; Gina L Razidlo; Andrew L Feldman
Journal:  Small GTPases       Date:  2017-01-06

Review 4.  Recent Progress in the Understanding of Angioimmunoblastic T-cell Lymphoma.

Authors:  Manabu Fujisawa; Shigeru Chiba; Mamiko Sakata-Yanagimoto
Journal:  J Clin Exp Hematop       Date:  2017

5.  Author reply to Comment on: Frequent CTLA4-CD28 gene fusion in diverse types of T-cell lymphoma, by Yoo et al.

Authors:  H Y Yoo; P Kim; W S Kim; S H Lee; S Kim; S Y Kang; H Y Jang; J E Lee; J Kim; S J Kim; Y H Ko; S Lee
Journal:  Haematologica       Date:  2016-05-31       Impact factor: 9.941

6.  Comment on: Frequent CTLA4-CD28 gene fusion in diverse types of T-cell lymphoma, by Yoo et al.

Authors:  Qiang Gong; Chao Wang; Joseph Rohr; Andrew L Feldman; Wing C Chan; Timothy W McKeithan
Journal:  Haematologica       Date:  2016-05-31       Impact factor: 9.941

7.  Recurrent MSC E116K mutations in ALK-negative anaplastic large cell lymphoma.

Authors:  Rebecca A Luchtel; Michael T Zimmermann; Guangzhen Hu; Surendra Dasari; Manli Jiang; Naoki Oishi; Hailey K Jacobs; Yu Zeng; Tanya Hundal; Karen L Rech; Rhett P Ketterling; Jeong-Heon Lee; Bruce W Eckloff; Huihuang Yan; Krutika S Gaonkar; Shulan Tian; Zhenqing Ye; Marshall E Kadin; Jagmohan Sidhu; Liuyan Jiang; Jesse Voss; Brian K Link; Sergei I Syrbu; Fabio Facchetti; N Nora Bennani; Susan L Slager; Tamas Ordog; Jean-Pierre Kocher; James R Cerhan; Stephen M Ansell; Andrew L Feldman
Journal:  Blood       Date:  2019-05-17       Impact factor: 22.113

8.  RNA fusions involving CD28 are rare in peripheral T-cell lymphomas and concentrate mainly in those derived from follicular helper T cells.

Authors:  David Vallois; Aurélie Dupuy; Francois Lemonnier; George Allen; Edoardo Missiaglia; Virginie Fataccioli; Nicolas Ortonne; Aline Clavert; Richard Delarue; Marie-Christine Rousselet; Bettina Fabiani; Francisco Llamas-Gutierrez; Seishi Ogawa; Margot Thome; Young Hyeh Ko; Keisuke Kataoka; Philippe Gaulard; Laurence de Leval
Journal:  Haematologica       Date:  2018-03-15       Impact factor: 9.941

Review 9.  Coinhibitory Pathways in the B7-CD28 Ligand-Receptor Family.

Authors:  Frank A Schildberg; Sarah R Klein; Gordon J Freeman; Arlene H Sharpe
Journal:  Immunity       Date:  2016-05-17       Impact factor: 31.745

10.  Genomic landscape of young ATLL patients identifies frequent targetable CD28 fusions.

Authors:  Noriaki Yoshida; Kay Shigemori; Nicholas Donaldson; Christopher Trevisani; Nicolas A Cordero; Kristen E Stevenson; Xia Bu; Fumiko Arakawa; Mai Takeuchi; Koichi Ohshima; Akinori Yoda; Samuel Y Ng; David M Weinstock
Journal:  Blood       Date:  2020-04-23       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.